130047-14-2

Basic information

• Product Name: BENZOIC ACID, 4-[(CHLOROSULFONYL)METHYL]-, METHYL ESTER
• Synonyms: Methyl 4-[(chlorosulfonyl)methyl]benzoate;BENZOIC ACID, 4-[(CHLOROSULFONYL)METHYL]-, METHYL ESTER;[4-(Methoxycarbonyl)phenyl]methanesulphonyl chloride;[4-(Methoxycarbonyl)phenyl]methanesulphonyl chloride 95%;Methyl 4-[(chlorosulphonyl)methyl]benzoate;Methyl 4-[(chlorosulphonyl)methyl]benzoate 95%;Methyl4-[(chlorosulphonyl)methyl]benzoate95%
• CAS NO: 130047-14-2
• Molecular Formula: C₉H₉ClO₄S
• Molecular Weight: 248.68
• Mol File: 130047-14-2.mol
• Article Data: 5

Chemical Properties

• Melting Point: 116 °C
• Boiling Point: 373.9 °C at 760 mmHg
• Flash Point: 179.9 °C
• Appearance: /
• Density: 1.412 g/cm³
• Vapor Pressure: 8.69E-06mmHg at 25°C
• Refractive Index: 1.55
• CAS DataBase Reference: BENZOIC ACID, 4-[(CHLOROSULFONYL)METHYL]-, METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: BENZOIC ACID, 4-[(CHLOROSULFONYL)METHYL]-, METHYL ESTER(130047-14-2)
• EPA Substance Registry System: BENZOIC ACID, 4-[(CHLOROSULFONYL)METHYL]-, METHYL ESTER(130047-14-2)

Safety Data

• Hazard Codes: C,Xn
• Statements: 22
• Hazardous Substances Data: 130047-14-2(Hazardous Substances Data)

Usage

General Description

BENZOIC ACID, 4-[(CHLOROSULFONYL)METHYL]-, METHYL ESTER is a chemical compound that consists of benzoic acid with a 4-[(chlorosulfonyl)methyl] group and a methyl ester functional group. It is commonly used as an intermediate in the synthesis of pharmaceutical compounds and agricultural products. This chemical compound is known for its antibacterial and antifungal properties and is often used as a preservative in food and cosmetics. It is an important ingredient in the production of fragrances, flavorings, and other industrial products. This chemical compound has the potential for various industrial applications due to its unique chemical structure and properties.

InChI:InChI=1/C9H9ClO4S/c1-14-9(11)8-4-2-7(3-5-8)6-15(10,12)13/h2-5H,6H2,1H3

Upstream product

• 46463-51-8 3-MeOOC-Bzl-SO₃^(1-)*Na⁽¹⁺⁾ 
• 2417-72-3 Methyl 4-(bromomethyl)benzoate 

Downstream Products

• 130046-29-6 4-[N (4-Fluoro-2-trifluoromethyl-phenyl)sulfamoylmethyl]-benzoic acid methyl ester 
• 617691-24-4 4-(pyridin-3-ylsulfamoylmethyl)benzoic acid methyl ester 
• 1021707-70-9 3-MeOOC-Bzls-d-Ppg-OH 
• 1417156-38-7 1-(4-methoxycarbonylphenyl)-3-phenyl-2-thia-3-azabicyclo[3.1.0]hexane 2,2-dioxide 
• 1417156-24-1 N-allyl-1-(4-methoxycarbonylphenyl)-N-phenylmethanesulfonamide 
• 1083334-82-0 1-(4-methoxycarbonylphenyl)-N-phenylmethanesulfonamide 
• 110654-40-5 methyl 4-(sulfamoylmethyl)benzoate 
• 1397749-97-1 (S)-3-[6,6-dimethyl-5-(4-morpholin-4-ylmethylphenyl)-4,4-dioxo-5,6-dihydro-4H-4lambda6-[1,4,3]-oxathiazin-2-ylamino]-3-(2-fluorophenyl)propan-1-ol 
• 1397714-99-6 N-(2,4-dimethoxybenzyl)-C-(4-hydroxymethylphenyl)methanesulfonamide 

Relevant articles and documents

SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: (Formula AA) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγInverse Agonist for Treatment of Castration-Resistant Prostate Cancer

We report the design, optimization, and biological evaluation of nuclear receptor RORγinverse agonists as therapeutic agents for prostate cancer treatment. The most potent compound 27 (designated as XY101) exhibited cellular activity with an IC50/su

TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE

The invention relates to inhibitors of trypsin-like serine proteases of the general formula (I) which, as well as plasmin, also inhibit plasma kallikrien, and to their preparation and use as medicaments, preferably for treatment of blood loss, especially in the case of hyperfibrinolytic states, in organ transplants or heart surgery interventions, in particular with a cardiopulmonary bypass, or as a constituent of a fibrin adhesive.